Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells

Molecular Pharmacology

Volumn 84, Issue 2, 2013, Pages 227-235

  Zhu, Weizhong ^a   Tilley, Douglas G ^a   Myers, Valerie D ^a   Coleman, Ryan C ^a   Feldman, Arthur M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BETA ARRESTIN 1; BISINDOLYLMALEIMIDE; CASPASE 3; CASPASE 7; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C; SMALL INTERFERING RNA; VASOPRESSIN V1A RECEPTOR;

ARTICLE; CELL DAMAGE; CELL DEATH; CELL HYPOXIA; CELL STRESS; CELL SURVIVAL; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE SILENCING; MYOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; SIGNAL TRANSDUCTION;

ANIMALS; ARGININE VASOPRESSIN; ARRESTINS; CASPASE 3; CASPASE 7; CELL DEATH; CELL SURVIVAL; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 5; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MYOBLASTS; PHOSPHORYLATION; PROTEIN KINASE C; RATS; RECEPTORS, VASOPRESSIN;

EID: 84880589600     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.086322     Document Type: Article

References (38)

1. Ahn S, Kim J, Hara MR, Ren XR, and Lefkowitz RJ (2009) beta-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem 284:8855-8865.
2. Benovic JL, Strasser RH, Caron MG, and Lefkowitz RJ (1986) Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA 83:2797-2801.
3. Berrada K, Plesnicher CL, Luo X, and Thibonnier M (2000) Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. J Biol Chem 275: 27229-27237.
4. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, and Burnett JC, Jr (2011) Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4:770-778.
5. Chen WC and Chen CC (1999) Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase. Endocrinology 140:1639-1648.
6. de Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, and Clauser E (1994) Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 356:215-220.
7. Dorn GW, 2nd (2009) GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med (Berl) 87:455-463.
8. Dorn GW, 2nd and Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537.
9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, and Yusuf S (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-1729.
10. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, and Traver B et al. (2012) A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 17:485-509.
11. Guo S, Olm-Shipman A, Walters A, Urciuoli WR, Devito S, Nadtochiy SM, Wojtovich AP, and Brookes PS (2012) A cell-based phenotypic assay to identify cardioprotective agents. Circ Res 110:948-957.
12. Hammes A, Oberdorf S, Strehler EE, Stauffer T, Carafoli E, Vetter H, and Neyses L (1994) Differentiation-specific isoform mRNA expression of the calmodulindependent plasma membrane Ca(21)-ATPase. FASEB J 8:428-435.
13. Hausdorff WP, Caron MG, and Lefkowitz RJ (1990) Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 4:2881-2889.
14. Heitzler D, Durand G, Gallay N, Rizk A, Ahn S, Kim J, Violin JD, Dupuy L, Gauthier C, and Piketty V et al. (2012) Competing G protein-coupled receptor kinases balance G protein and b-arrestin signaling (Abstract). Mol Syst Biol 8:590.
15. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, and Schultz G (1991) Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69:1476-1486.
16. Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, and Tanoue A (2007) Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol 559:89-97.
17. Huang ZM, Gold JI, and Koch WJ (2011) G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci 16:3047-3060.
18. Indrambarya T, Boyd JH, Wang Y, McConechy M, and Walley KR (2009) Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice (Abstract). Crit Care 13:R98.
19. Innamorati G, Sadeghi H, and Birnbaumer M (1998) Transient phosphorylation of the V1a vasopressin receptor. J Biol Chem 273:7155-7161.
20. Innamorati G, Sadeghi H, and Birnbaumer M (1999) Phosphorylation and recycling kinetics of G protein-coupled receptors. J Recept Signal Transduct Res 19:315-326.
21. Kim KS, Abraham D, Williams B, Violin JD, Mao L, and Rockman HA (2012) b-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303:H1001-H1010.
22. Koch WJ, Hawes BE, Inglese J, Luttrell LM, and Lefkowitz RJ (1994) Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem 269:6193-6197.
23. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, and Konstam MA et al.; EVEREST trial investigators (2013) Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 6:47-52.
24. Li X, Chan TO, Myers V, Chowdhury I, Zhang XQ, Song J, Zhang J, Andrel J, Funakoshi H, and Robbins J et al. (2011) Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gaq-mediated cell signaling. Circulation 124: 572-581.
25. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, and Brownstein MJ (1992) Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357:336-339.
26. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, and Lefkowitz RJ (2001) Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449-2454.
27. Lymperopoulos A, Rengo G, and Koch WJ (2012) GRK2 inhibition in heart failure: something old, something new. Curr Pharm Des 18:186-191.
28. Morel A, O'Carroll AM, Brownstein MJ, and Lolait SJ (1992) Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356:523-526.
29. Nazari A, Sadr SS, Faghihi M, Imani A, and Moghimian M (2011) The cardioprotective effect of different doses of vasopressin (AVP) against ischemiareperfusion injuries in the anesthetized rat heart. Peptides 32:2459-2466.
30. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, and Lefkowitz RJ et al. (2007) Beta-arrestinmediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458.
31. Reilly BA, Brostrom MA, and Brostrom CO (1998) Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic/endoplasmic reticulum Ca2+ stores. J Biol Chem 273:3747-3755.
32. Rosner MH and Ronco C (2010) Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism. Congest Heart Fail 16 (Suppl 1):S7-S14.
33. Sipido KR and Marban E (1991) L-type calcium channels, potassium channels, and novel nonspecific cation channels in a clonal muscle cell line derived from embryonic rat ventricle. Circ Res 69:1487-1499.
34. Tilley DG (2011) G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 109:217-230.
35. Tran K, Zha X, Chan M, and Choy PC (1995) Enhancement of phospholipid hydrolysis in vasopressin-stimulated BHK-21 and H9c2 cells. Mol Cell Biochem 151: 69-76.
36. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging b-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
37. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, and Xiao RP (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98:1607-1612.
38. Zmily HD, Alani A, and Ghali JK (2013) Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment. Expert Opin Drug Metab Toxicol 9:645-655. Institute Institute